Validation of Plasmodium vivax centromere and promoter activities using Plasmodium yoelii
Open Access
- 20 December 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12), e0226884
- https://doi.org/10.1371/journal.pone.0226884
Abstract
Plasmodium vivax is the leading cause of malaria outside Africa and represents a significant health and economic burden on affected countries. A major obstacle for P. vivax eradication is the dormant hypnozoite liver stage that causes relapse infections and the limited antimalarial drugs that clear this stage. Advances in studying the hypnozoite and other unique biological aspects of this parasite are hampered by the lack of a continuous in vitro laboratory culture system and poor availability of molecular tools for genetic manipulation. In this study, we aim to develop molecular tools that can be used for genetic manipulation of P. vivax. A putative P. vivax centromere sequence (PvCEN) was cloned and episomal centromere based plasmids expressing a GFP marker were constructed. Centromere activity was evaluated using a rodent malaria parasite Plasmodium yoelii. A plasmid carrying PvCEN was stably maintained in asexual-stage parasites in the absence of drug pressure, and approximately 45% of the parasites retained the plasmid four weeks later. The same retention rate was observed in parasites possessing a native P. yoelii centromere (PyCEN)-based control plasmid. The segregation efficiency of the plasmid per nuclear division was > 99% in PvCEN parasites, compared to ~90% in a control parasite harboring a plasmid without a centromere. In addition, we observed a clear GFP signal in both oocysts and salivary gland sporozoites isolated from mosquitoes. In blood-stage parasites after liver stage development, GFP positivity in PvCEN parasites was comparable to control PyCEN parasites. Thus, PvCEN plasmids were maintained throughout the parasite life cycle. We also validated several P. vivax promoter activities and showed that hsp70 promoter (~1 kb) was active throughout the parasite life cycle. This is the first data for the functional characterization of a P. vivax centromere that can be used in future P. vivax biological research.Keywords
Funding Information
- Japan Society for the Promotion of Science (23659215)
- Bill and Melinda Gates Foundation (OPP1023643)
- Bill and Melinda Gates Foundation (OPP1023643)
This publication has 34 references indexed in Scilit:
- Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malariaPLoS Neglected Tropical Diseases, 2018
- World Trade Report 2018World Trade Report, 2018
- Advancing Research Models and Technologies to Overcome Biological Barriers to Plasmodium vivax ControlTrends in Parasitology, 2017
- The Biology of Plasmodium vivaxCold Spring Harbor Perspectives in Medicine, 2017
- Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivaxActa Tropica, 2016
- Differential CYP 2D6 Metabolism Alters Primaquine PharmacokineticsAntimicrobial Agents and Chemotherapy, 2015
- Editing thePlasmodium vivaxGenome, Using Zinc-Finger NucleasesThe Journal of Infectious Diseases, 2014
- Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax MalariaThe New England Journal of Medicine, 2013
- The metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malaria Journal, 2013
- Transient transfection of Plasmodium vivax blood stage parasitesMolecular and Biochemical Parasitology, 2006